AI enhances diagnostic accuracy across laboratory medicine and anatomic pathology — from automated specimen analysis to AI-powered cancer detection and molecular diagnostics interpretation.
Diagnostics and pathology sit at the foundation of clinical decision-making, with 70% of medical decisions informed by laboratory and pathology results. AI is transforming both clinical pathology (laboratory testing) and anatomic pathology (tissue analysis) by automating routine analysis, improving diagnostic accuracy, and enabling precision medicine approaches that match patients with optimal treatments based on their specific disease biology.
Digital pathology combined with AI represents a paradigm shift in cancer diagnosis. Paige AI received the first FDA clearance for AI-based cancer diagnostics in pathology, with its prostate cancer detection system demonstrating improved sensitivity for identifying cancerous tissue on whole-slide images. PathAI provides AI-powered pathology analysis for clinical trials and pharmaceutical development, with algorithms that grade tumors, quantify biomarkers, and predict treatment response from tissue morphology. Aiforia's platform at Memorial Pathology analyzes breast, prostate, and PD-L1 lung specimens with AI, standardizing assessment across pathologists and reducing inter-observer variability. These tools digitize the traditionally microscope-based pathology workflow, enabling remote consultation, AI-assisted quality assurance, and quantitative analysis that surpasses subjective human grading.
Molecular diagnostics and precision medicine represent the growing edge of diagnostic AI. Tempus integrates genomic profiling with clinical data analysis to match cancer patients with targeted therapies, operating a CLIA-certified laboratory used by hundreds of oncology practices. AI interprets next-generation sequencing results — distinguishing clinically actionable mutations from variants of uncertain significance across panels that may identify hundreds of genetic variants. Prenosis's FDA-cleared sepsis diagnostic demonstrates AI's ability to combine routine laboratory values into predictive scores that outperform traditional clinical criteria. As molecular testing expands beyond oncology into cardiology, neurology, and pharmacogenomics, AI will be essential for integrating complex multi-omics data into clinically actionable diagnostic reports.
AI analyzes digitized tissue slides (whole-slide images) using computer vision to detect cancer cells, grade tumors, and quantify biomarkers. Paige AI's FDA-cleared system identifies areas of prostate tissue that contain cancer, guiding pathologists to regions that need detailed review. PathAI algorithms grade tumors on standardized scales with reproducibility that exceeds human inter-observer agreement. For biomarker quantification (PD-L1, HER2, Ki-67), AI provides objective percentage scores rather than subjective estimates. The practical impact is fewer missed diagnoses, more consistent grading, and faster turnaround for the 1.9 million new cancer cases diagnosed annually in the US.
Get your AI solutions in front of decision-makers actively researching this space.
Learn about vendor listings →
AI Roadmap — Two hours charting for every hour with patients. Prior auth eating your back office. Both fixable, in the right order. 12 pages, 72 hours.